IL1B rs1143634: Dietary Fatty Acids and Inflammation

What each genotype means

Genetic Location and Molecular Characteristics

The single nucleotide polymorphism rs1143634 is situated on chromosome 2 within exon 5 of the IL1B gene, historically cataloged in scientific literature as +3954 C>T (or +3953 depending on numbering conventions). At this specific genomic position, the major allele is cytosine (C), while the minor alternative allele is thymine (T). In various literature reports, strand annotations may present this substitution as guanine (G) to adenine (A). Because it resides within an exonic region of the gene, researchers have extensively studied rs1143634 to evaluate whether the nucleotide change influences messenger RNA stability, translation efficiency, or secretion levels of the interleukin-1 beta protein. Rather than causing monogenic disease, rs1143634 acts as a common regulatory polymorphism that subtly modulates baseline physiological states across human populations.

The Biological Role of the IL1B Gene

The IL1B gene provides the genetic blueprint for producing interleukin-1 beta (IL-1β), an essential pro-inflammatory cytokine primarily produced by monocytes, tissue macrophages, and dendritic cells. Interleukin-1 beta acts as a potent molecular alarm signal during immune defense, triggering local vascular changes, leukocyte recruitment, fever induction, and the synthesis of downstream acute-phase reactants such as C-reactive protein (CRP) and interleukin-6. While robust IL-1β signaling is crucial for clearing infectious pathogens and initiating tissue repair, chronic dysregulation or persistent low-grade overproduction has been implicated in long-term metabolic disruption, adipose tissue inflammation, insulin resistance, and atherogenesis. Consequently, genetic differences that modulate IL1B transcription or cytokine release can tilt the balance between acute protective immunity and chronic inflammatory signaling.

Nutrigenomic Interactions and Inflammatory Markers

In nutrigenomics, rs1143634 has drawn significant interest due to gene-diet interaction studies investigating lipid metabolism and inflammatory profiles. Observational research indicates that individuals carrying the minor T (or A) allele may display altered baseline cytokine production and differential sensitivity to dietary anti-inflammatory fats, notably long-chain omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA). In some cohort studies, the anti-inflammatory efficacy of dietary omega-3 intake in reducing markers of metabolic syndrome or inflammatory cytokines varied depending on rs1143634 genotype. However, overall scientific evidence remains categorized as limited. Findings across distinct cohorts have occasionally produced mixed results, with some cohorts observing protective effects and others finding altered susceptibility to inflammatory conditions or elevated baseline markers. As a result, rs1143634 cannot be considered an independent diagnostic or prognostic marker on its own.

Population Distribution and Ancestral Patterns

The minor allele of rs1143634 exhibits substantial frequency differences across global populations. In European cohorts, the minor allele frequency typically falls between 20% and 30%, making heterozygous carriers common in populations of European ancestry. In contrast, East Asian and African populations demonstrate noticeably lower frequencies of the alternative allele, often dropping below 5% to 10% in certain sub-cohorts. Such pronounced ancestral divergence underscores why genetic association findings often fail to replicate across ethnically diverse populations. When evaluating genetic risk or nutritional interactions involving rs1143634, individual ancestral background must be accounted for to prevent inaccurate inferences regarding baseline inflammatory susceptibility.

Clinical Realities: What You Can and Cannot Do

Knowing your rs1143634 genotype offers educational context into baseline inflammatory pathways, but it cannot diagnose chronic illness, autoimmune disorders, or metabolic conditions. A genetic tendency toward altered cytokine production is only one small component of overall immune function, interacting dynamically with lifestyle factors, physical activity, sleep quality, gut microbiota, and overall nutritional balance. You should not begin high-dose dietary supplements, alter cardiovascular medication, or modify medical treatment based solely on this genotype. If you are exploring dietary changes—such as increasing intake of fatty fish, walnuts, or omega-3 fatty acids—or if you have questions regarding medication and systemic inflammation, discuss these strategies directly with a registered dietitian, physician, or qualified healthcare professional.

Frequently asked questions

Sources & further reading